Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

701. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. (Abstract)

Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Vitamin K antagonists, the current standard treatment for prophylaxis against stroke and systemic embolism in patients with atrial fibrillation, require regular monitoring and dose adjustment; an unmonitored, fixed-dose anticoagulant regimen would be preferable. The aim of this randomised, open-label non-inferiority trial (...) was to compare the efficacy and safety of idraparinux with vitamin K antagonists.Patients with atrial fibrillation at risk for thromboembolism were randomly assigned to receive either subcutaneous idraparinux (2.5 mg weekly) or adjusted-dose vitamin K antagonists (target of an international normalised ratio of 2-3). Assessment of outcome was done blinded to treatment. The primary efficacy outcome was the cumulative incidence of all stroke and systemic embolism. The principal safety outcome was clinically

2008 Lancet Controlled trial quality: predicted high

702. Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery

Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

703. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W) Full Text available with Trip Pro

Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W) In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation. However, because OAC carries important bleeding complications, risk

2008 EvidenceUpdates Controlled trial quality: uncertain

704. Relation of Recurrence of Atrial Fibrillation After Non-ST-Elevation Acute Myocardial Infarction to Left Atrial Abnormality (Abstract)

Relation of Recurrence of Atrial Fibrillation After Non-ST-Elevation Acute Myocardial Infarction to Left Atrial Abnormality Atrial fibrillation (AF) is common during the course of acute myocardial infarction and is associated with left atrial (LA) dilatation. However, the role of LA depolarization abnormality on the electrocardiogram (ECG) in the setting of LA dilatation was not studied in this context. Patients admitted with non-ST-segment elevation myocardial infarction (NSTEMI) who developed (...) new-onset AF (International Classification of Diseases, Ninth Revision code 427.31) were prospectively identified. Baseline ECGs and echocardiograms before the admission event were reviewed. Follow-up was directed toward pertinent cardiovascular events, atrial tachyarrhythmias, and death as end points. Of 101 patients with NSTEMI who had new-onset AF, 88 had current echocardiograms and 69 had LA dilatation (78%). Total follow-up was 24 months (mean 21.4). Prolonged P-wave duration (> or =110 ms

2008 EvidenceUpdates

705. Management of atrial fibrillation. Full Text available with Trip Pro

Management of atrial fibrillation. Atrial fibrillation is the most common sustained cardiac rhythm disorder, and confers a substantial mortality and morbidity from stroke, thromboembolism, heart failure, and impaired quality of life. With the increasingly elderly population in the developed world, as well as improvements in the management of myocardial infarction and heart failure, the prevalence of atrial fibrillation is increasing, resulting in a major public-health problem. This Review aims (...) to provide an overview on the modern management of atrial fibrillation, with particular emphasis on pharmacological and non-pharmacological approaches. Irrespective of a rate-control or rhythm-control strategy, stroke prevention with appropriate thromboprophylaxis still remains central to the management of this common arrhythmia. Electrophysiological approaches could hold some promise for a curative approach in atrial fibrillation.

2007 Lancet

706. WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. (Abstract)

WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Atrial fibrillation (AF) carries a high risk of stroke and other thromboembolic events. Appropriate use of drugs to prevent thromboembolism in patients with AF involves comparing the patient's risk of stroke to the risk of hemorrhage from medication use.To quantify risk of stroke, major hemorrhage and death from using medications that have been rigorously evaluated for prevention

2007 Cochrane

707. Negative D-dimer may allow safe early cardioversion of atrial fibrillation

Negative D-dimer may allow safe early cardioversion of atrial fibrillation BestBets: Negative D-dimer may allow safe early cardioversion of atrial fibrillation Negative D-dimer may allow safe early cardioversion of atrial fibrillation Report By: Richard Body - Specialist Registrar Search checked by Babak Allie - Specialist Registrar Institution: Manchester Royal Infirmary Date Submitted: 30th August 2005 Date Completed: 29th May 2007 Last Modified: 19th April 2007 Status: Green (complete) Three (...) Part Question In [patients with atrial fibrillation being considered for electrical or pharmacologic cardioversion] does [measurement of D-dimer] allow [exclusion of atrial thrombus]? Clinical Scenario A 45 year-old man presents to the Emergency Department with a 48-hour history of palpitations, postural light-headedness and exertional dyspnoea. ECG demonstrates atrial fibrillation (AF) at a rate of 130 beats/minute. There are no apparent reversible causes following history, examination, chest

2007 BestBETS

708. Pulse pressure and risk of new-onset atrial fibrillation. Full Text available with Trip Pro

Pulse pressure and risk of new-onset atrial fibrillation. Atrial fibrillation (AF) is responsible for considerable morbidity and mortality, making identification of modifiable risk factors a priority. Increased pulse pressure, a reflection of aortic stiffness, increases cardiac load and may increase AF risk.To examine relations between pulse pressure and incident AF.Prospective, community-based observational cohort in Framingham, Mass, including 5331 Framingham Heart Study participants aged 35 (...) (HR, 1.14 per 20-mm Hg increment; 95% CI, 1.04-1.25; P = .006); however, if diastolic pressure was added, model fit improved and the diastolic relation was inverse (adjusted HR, 0.87 per 10-mm Hg increment; 95% CI, 0.78-0.96; P = .01), consistent with a pulse pressure effect. Among patients with interpretable echocardiographic images, the association between pulse pressure and AF persisted in models that adjusted for baseline left atrial dimension, left ventricular mass, and left ventricular

2007 JAMA

709. Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation

Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation Article Text Therapeutics Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic

2007 Evidence-Based Medicine

710. Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation

Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation Article Text Therapeutics Review: angiotensin converting

2007 Evidence-Based Medicine

711. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. Full Text available with Trip Pro

Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. Atrial fibrillation (AF) is the most common arrhythmia to occur after cardiac surgery. An exaggerated inflammatory response has been proposed to be one etiological factor.To test whether intravenous corticosteroid administration after cardiac surgery prevents AF after cardiac surgery.A double-blind, randomized multicenter trial (study enrollment August 2005-June 2006) in 3 university

2007 JAMA Controlled trial quality: predicted high

712. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. Full Text available with Trip Pro

Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. To assess whether screening improves the detection of atrial fibrillation (cluster randomisation) and to compare systematic and opportunistic screening.Multicentred cluster randomised controlled trial, with subsidiary trial embedded within the intervention arm.50 primary care centres in England, with further individual randomisation of patients (...) detection rate of new cases of atrial fibrillation was 1.63% a year in the intervention practices and 1.04% in control practices (difference 0.59%, 95% confidence interval 0.20% to 0.98%). Systematic and opportunistic screening detected similar numbers of new cases (1.62% v 1.64%, difference 0.02%, -0.5% to 0.5%).Active screening for atrial fibrillation detects additional cases over current practice. The preferred method of screening in patients aged 65 or over in primary care is opportunistic pulse

2007 BMJ Controlled trial quality: predicted high

713. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. Full Text available with Trip Pro

Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. Amiodarone is effective in maintaining sinus rhythm in atrial fibrillation but is associated with potentially serious toxic effects. Dronedarone is a new antiarrhythmic agent pharmacologically related to amiodarone but developed to reduce the risk of side effects.In two identical multicenter, double-blind, randomized trials, one conducted in Europe (ClinicalTrials.gov number, NCT00259428 [ClinicalTrials.gov (...) to the first recurrence of atrial fibrillation or flutter.In the European trial, the median times to the recurrence of arrhythmia were 41 days in the placebo group and 96 days in the dronedarone group (P=0.01). The corresponding durations in the non-European trial were 59 and 158 days (P=0.002). At the recurrence of arrhythmia in the European trial, the mean (+/-SD) ventricular rate was 117.5+/-29.1 beats per minute in the placebo group and 102.3+/-24.7 beats per minute in the dronedarone group (P<0.001

2007 NEJM Controlled trial quality: predicted high

714. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. Full Text available with Trip Pro

Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. Conventional dual-chamber pacing maintains atrioventricular synchrony but results in high percentages of ventricular pacing, which causes ventricular desynchronization and has been linked to an increased risk of atrial fibrillation in patients with sinus-node disease.We randomly assigned 1065 patients with sinus-node disease, intact atrioventricular conduction, and a normal QRS interval to receive conventional (...) was lower in dual-chamber minimal ventricular pacing than in conventional dual-chamber pacing (9.1% vs. 99.0%, P<0.001), whereas the percentage of atrial beats that were paced was similar in the two groups (71.4% vs. 70.4%, P=0.96). Persistent atrial fibrillation developed in 110 patients, 68 (12.7%) in the group assigned to conventional dual-chamber pacing and 42 (7.9%) in the group assigned to dual-chamber minimal ventricular pacing. The hazard ratio for development of persistent atrial fibrillation

2007 NEJM Controlled trial quality: predicted high

715. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. (Abstract)

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Anticoagulants are more effective than antiplatelet agents at reducing stroke risk in patients with atrial fibrillation, but whether this benefit outweighs the increased risk of bleeding in elderly patients is unknown. We assessed whether warfarin reduced risk of major stroke, arterial (...) embolism, or other intracranial haemorrhage compared with aspirin in elderly patients.973 patients aged 75 years or over (mean age 81.5 years, SD 4.2) with atrial fibrillation were recruited from primary care and randomly assigned to warfarin (target international normalised ratio 2-3) or aspirin (75 mg per day). Follow-up was for a mean of 2.7 years (SD 1.2). The primary endpoint was fatal or disabling stroke (ischaemic or haemorrhagic), intracranial haemorrhage, or clinically significant arterial

2007 Lancet Controlled trial quality: predicted high

716. Management and Consequences of Atrial Fibrillation

Management and Consequences of Atrial Fibrillation Management and Consequences of Atrial Fibrillation – Clinical Correlations Search Management and Consequences of Atrial Fibrillation August 2, 2007 4 min read . In brief, the articles highlighted the risks of thromboembolism, the lack of very successful medical therapies, and the growing demand for catheter-based atrial fibrillation ablation procedures. As a cardiology fellow on the consultation service at a teaching hospital in western (...) Pennsylvania, I find that atrial fibrillation is perhaps the most common reason for consultation. I would like to share a brief overview of an approach to atrial fibrillation management and also clarify some points discussed by the articles. There are several questions that should be answered when seeing a patient in consultation for atrial fibrillation: 1) Is the atrial fibrillation paroxysmal or persistent? 2) Is the patient symptomatic from the arrhythmia? 3) Is a rate control or a rhythm control

2007 Clinical Correlations

717. Vagally-induced Atrial Fibrillation

Vagally-induced Atrial Fibrillation Vagally-induced Atrial Fibrillation – Clinical Correlations Search Vagally-induced Atrial Fibrillation November 7, 2007 3 min read | | 6 comments on “ Vagally-induced Atrial Fibrillation ” This has been my experience since 1985 when I was 33. Have been on Norpace since developing chemically induced lupus from procainimide in 1995. No ER gets this. Most of my episodes self correct. But every now and again I have one that dos not and I tell them the above

2007 Clinical Correlations

718. Atrial Fibrillation Part 2: Additional Words of Wisdom

Atrial Fibrillation Part 2: Additional Words of Wisdom Atrial Fibrillation Part 2: Additional Words of Wisdom – Clinical Correlations Search Atrial Fibrillation Part 2: Additional Words of Wisdom August 3, 2007 2 min read | | Sites We Follow: Useful Links: Questions? Comments? Contact us! © New York University. All rights reserved. Electronic ISSN 1944-0030. The content of this site is intended for health care professionals.

2007 Clinical Correlations

719. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis

Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

720. Warfarin reduced major stroke more than aspirin in elderly patients with atrial fibrillation in primary care Full Text available with Trip Pro

Warfarin reduced major stroke more than aspirin in elderly patients with atrial fibrillation in primary care Warfarin reduced major stroke more than aspirin in elderly patients with atrial fibrillation in primary care. | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Warfarin reduced major stroke more than aspirin in elderly patients with atrial fibrillation in primary care. Article Text Therapeutics Warfarin reduced major stroke more than

2007 Evidence-Based Medicine